C. difficile is not another GI pathogen: Why Testing Strategy matters

In hospitals across Europe, Clostridioides difficile infection (CDI) remains a persistent and costly challenge. Despite decades of clinical experience and increasingly sophisticated diagnostics, accurately identifying those who truly have CDI and who does not remain a challenge for clinicians and microbiology laboratories alike. At the heart of the issue lies a fundamental truth: diagnosing CDI is not a single test decision, but a clinical process that demands nuance, context, and stewardship. ^1.2

Recent discussions show that even well-intentioned diagnostic strategies can lead to both underdiagnosis and overdiagnosis, directly impacting patient outcomes, infection control, and antibiotic use.¹

When sensitivity is not the whole story

Molecular tests, particularly NAATs, have transformed CDI diagnostics. NAATs offer greater sensitivity and specificity than toxin enzyme immunoassays or GDH screening, making them central to many European testing algorithms.³ However, factors beyond sensitivity also require attention.

Sensitivity alone does not guarantee clinical certainty. A positive molecular result confirms toxigenic C. difficile but does not always indicate active infection. Asymptomatic colonization is common in healthcare settings. Without careful interpretation, sensitive tests may identify the organism even when it is not causing disease.^4.5

The hidden pitfalls of multistep algorithms

To balance accuracy and practicality, many laboratories rely on multistep diagnostic pathways combining GDH, toxin testing, and NAATs. While these algorithms aim to improve predictive value, they introduce their own vulnerabilities.^6.7

GDH screening, for example, can produce both false negatives and false positives. Some Clostridium species and even unrelated organisms may cross‑react, while certain toxigenic strains may be missed entirely. Toxin assays, meanwhile, are prone to variability and can generate misleading results when used in isolation.^6.8

Certain strains challenge traditional assumptions. Some C. difficile isolates lack toxins A or B but carry binary toxin genes. Others, including epidemic ribotypes linked to severe disease, have genetic deletions that affect toxin regulation. Without accounting for these nuances, diagnostic tools may miss or delayed clinically significant cases.^6.9,10

What real-world evidence is telling us

Emerging clinical data are reshaping how laboratories think about CDI testing strategies. Studies evaluating reverse two-step algorithms and standalone NAAT approaches show tangible benefits: fewer hospital onset CDI cases, reduced antibiotic exposure, and more consistent infection control practices.^5,13

Building on these insights, a notable finding is that some NAAT-positive patients may test negative by GDH screening. Clinically, using GDH alone as a gatekeeper may result in missed diagnoses, allowing unidentified cases to contribute to hospital transmission.⁵

Conversely, treating every molecular positive without considering symptoms or risk factors risks unnecessary antibiotic use. This reinforces a central message: laboratory results must be interpreted through a clinical lens, not in isolation.^4,14

The stewardship imperative

As diagnostics become more powerful, the responsibility to use them wisely grows. Diagnostic stewardship, the principle of ordering the right test for the right patient at the right time, is now recognized as an essential partner to antimicrobial stewardship.^1.2

In CDI, stewardship means resisting reflex testing in low probability situations, avoiding repeat testing without clinical justification, and embedding decision support into ordering workflows. Evidence from hospitals implementing stewardship interventions have been associated with reductions in unnecessary testing and false‑positive results without clear evidence of increased missed diagnoses.^15,16

This is particularly relevant with the growing use of multiplex gastrointestinal panels. While these tools can rapidly identify a wide range of pathogens, they also increase the likelihood of detecting C. difficile colonization rather than infection. Studies indicate that only a minority of panel positive results ultimately represent true CDI, yet many patients still receive treatment.^5,17

Moving forward: integration, not isolation

The future of CDI diagnosis does not lie in a single “perfect” test. Instead, it depends on integrating advanced molecular diagnostics with clear institutional policies, clinical judgment, and stewardship frameworks.^1,18

Laboratories and clinicians must work together to define when testing is appropriate, how results should be interpreted, and how diagnostic pathways align with patient management goals. This integrated approach helps avoid harm, reduces unnecessary antibiotic exposure, and supports better infection control decisions.²

Ultimately, improving CDI diagnosis is not just about detecting bacteria. It is about understanding disease. And in an era of powerful diagnostics, that understanding has never mattered more.¹